Antibody–drug conjugates have emerged as a powerful tool to deliver highly targeted cancer therapies. Next-generation antibody-drug conjugate designs aim to push the envelope even further.
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's ...